Skip to main content

Research Finding

NUS Magnetic Pulse Therapy Eradicates Tumors in 75% of Preclinical Trials

Singapore – September 16, 2026 -- Researchers at the National University of Singapore (NUS) have eradicated tumours in 75 per cent of tested preclinical models using pulsed electromagnetic fields (PEMFs) alone, without chemotherapy, after just four 30-minute sessions. The study, led by Associate Professor Alfredo Franco-Obregón of the NUS Yong Loo Lin School of Medicine, was published in the journal Smart Medicine on June 4, 2026.

PEMF device already cleared Phase 1 human safety trials

The same PEMF device used in the study has completed Phase 1 clinical trials, confirming its safety in humans. The NUS team is now seeking partners to fund and conduct Phase 2 efficacy trials to evaluate treatment performance in patients.

Nature Study Validates PLA2G2D as New Checkpoint Beating PD-1 Resistance

South San Francisco, Calif. – September 15, 2026 -- Apeximmune Therapeutics said a peer-reviewed study published in Nature independently validates PLA2G2D as a novel immune checkpoint capable of overcoming resistance to anti-PD-1 cancer therapies, with the company's lead antibody AI-306 targeting an IND filing in the second quarter of 2027.

Two independent research teams identified the same target through different methods

Apeximmune's computational screen of more than 9,000 primary tumor samples from The Cancer Genome Atlas ranked PLA2G2D as its top novel checkpoint candidate, ahead of PD-1 and CTLA-4 in the same analysis. Working separately and without knowledge of Apeximmune's program, researchers at Erasmus University Medical Center in Rotterdam used spatial proteogenomic analysis of melanoma patient samples with divergent outcomes and arrived at PLA2G2D as a top hit in dendritic cell and macrophage populations linked to poorer prognosis.